Organovo Holdings, Inc. (ONVO)
ONVOPrice: $2.04
Fair Value: 🔒
🔒score
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammali... more
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate... more
Description
Shares
| Market Cap | $3.67M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Keith E. Murphy |
| IPO Date | 2012-02-14 | CAGR | — |
| Employees | 14 | Website | www.organovo.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ONVO chart loading...
Fundamentals
Technicals
| Enterprise Value | $-3.23M | P/E Ratio | -0.2 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 39.91 | P/B Ratio | 0.57 |
| P/CF Ratio | -0.52 | P/FCF Ratio | -0.54 |
| EPS | $-10.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 35.92% | Gross Margin | 0.98% |
| Operating Margin | -85.53% | Profit Margin | -13.99% |
| ROE | -0.33% | ROA | -0.17% |
| ROCE | -1.23% | Current Ratio | 4.52 |
| Quick Ratio | 4.52 | Cash Ratio | 4.23 |
| Debt/Equity | 0.09 | Interest Coverage | -867.5 |
| Altman Z Score | -39.23 | Piotroski Score | 4 |